Late Onset Neurometabolic Genetic Disorders

From Clinical to Molecular Aspects of Lysosomal and Peroxisomal Disease

Editors
Nicole Baumann, Paris Antonio Federico, Siena Kunihiko Suzuki, Chapel Hill, N.C.

82 figures and 46 tables, 1991
Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. All rights reserved.

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see 'Information for Readers and Subscribers').

© Copyright 1991 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland) Printed in Switzerland on acid-free paper by Boehm-Hutter AG, Druckerei, Reinach BL ISBN 3–8055–5524–5

Contents

Introduction
183

Baumann, N.; Federico, A.; Suzuki, K.

Introduction to Late Onset Neurometabolic Diseases

The First Alzheimer Disease Case: A Metachromatic Leukodystrophy?
Amaducci, L.; Sorbi, S.; Piacentini, S.; Bick, K.L. ................................. 186

Diagnosis and Pathogenesis of Late-Onset Genetic Metabolic Encephaloneuromyopathies
Federico, A ................................. 188

Biochemical Basis of Late-Onset Neurolipidosis
Conzelmann, E.; Sandhoff, K. ................................. 191

Neuropathology of Late Onset Gangliosidoses. A Review
Suzuki, K. ................................. 205

Clinical and Biological Aspects of Leukodystrophies

Adult Forms of Metachromatic Leukodystrophy: Clinical and Biochemical Approach
Baumann, N.; Masson, M.; Carreau, V.; Lefevre, M.; Herschkowitz, N.; Turpin, J.C. ................................. 211

Pseudodeficiencies of Arylsulfatase A and Galactocerebrosidase Activities
Wenger, D.A.; Louie, E ................................. 216

Molecular Genetics of Metachromatic Leukodystrophy

Phenotypic Consequences of Low Arylsulfatase A Genotypes (ASAp/ASAp and ASA-/ASAp): Does There Exist an Association with Multiple Sclerosis?
Kappler, J.; Potter, W.; Gieselmann, V.; Kiessling, W.; Friedl, W.; Propping, P. ................................. 228

Late-Onset Krabbe Disease (Globoid Cell Leukodystrophy): Clinical and Biochemical Features of 15 Cases
Kolodny, E.H.; Raghavan, S.; Krivit, W. ................................. 232

Symptomatology of Late Onset Krabbe's Leukodystrophy: The European Experience
Lyon, G.; Hagberg, B.; Evrard, Ph.; Allaire, G.; Pavone, L.; Vanier, M. ................................. 240

Leuko-Araiosis
Cerebrotendinous Xanthomatosis as a Multisystem Disease Mimicking Premature Ageing

Dotti M.T.; Salen G.; Federico A.

371